Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LGND files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsLigand Pharmaceuticals reports Q1 2026 earnings via press release
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
high
Company announced financial results for the three months ended March 31, 2026, through a press release furnished as an exhibit to this 8-K filing.
Item 2.02 verify on EDGAR → -
medium
The 8-K filing itself contains no financial figures or performance metrics; actual results are disclosed only in the attached press release (Exhibit 99.1).
8-K: Exhibits verify on EDGAR →
Summary
Ligand Pharmaceuticals filed an 8-K to announce its first quarter 2026 financial results. This is a routine earnings disclosure under Item 2.02, where companies furnish their quarterly performance to investors. The filing references a press release dated May 7, 2026, but does not include the actual financial data in the 8-K body itself.
Retail investors should review the attached press release (Exhibit 99.1) for the complete financial picture, including revenue, earnings per share, and any forward guidance. Standard earnings announcements like this are typically accompanied by a conference call where management discusses results and answers analyst questions. Watch for any subsequent filings or investor presentations that provide additional context on the quarter's performance and the company's outlook for the remainder of 2026.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 7, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references the press release as Exhibit 99.1. This is a standard earnings announcement filing under Item 2.02.
Event · Item 9.01 — Financial Statements and Exhibits
Ligand Pharmaceuticals filed an 8-K attaching a press release dated May 7, 2026; no material event details disclosed in the filing body.
Added in current filing · view on EDGAR →
Exhibit No. | Description | 99.1 | Press release dated May 7, 2026.
The 8-K references a press release dated May 7, 2026, attached as Exhibit 99.1. The filing body does not disclose the content or subject matter of the press release, so the nature of the event remains unknown without reviewing the exhibit itself.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify